Live search
TopFind is fetching the latest matches for your search.
We reviewed 59 live results for amgevita yuflyma hyrimoz adalimumab biosimilars and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Prescription Medicine and Biosimilar.
Source: Amgen Inc.
Description
Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes.
Best for
International patients, Uveitis treatment, Hidradenitis suppurativa care and Ankylosing spondylitis patients
Rating
Source: Amgevita
Description
A group of TNF inhibitor monoclonal antibody biosimilars recently approved in Singapore. These are indicated for managing conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Best for
Rheumatoid arthritis patients, Crohn’s disease treatment, Psoriatic arthritis care and Ulcerative colitis management
Rating
Source: Celltrion Healthcare
Description
Yuflyma is an adalimumab biosimilar, classified as a biologic Disease-Modifying Antirheumatic Drug (DMARD). It is used to treat immune-mediated inflammatory diseases by targeting and neutralizing TNF-alpha, helping to alleviate symptoms in conditions like psoriasis and arthritis.
Best for
Psoriatic arthritis, Inflammatory disease management and Biologic DMARD users
Rating
| Compare | Amgevita (adalimumab) | Amgevita / Yuflyma / Hyrimoz (Adalimumab Biosimilars) | Yuflyma (Adalimumab) |
|---|---|---|---|
| Source | Amgen Inc. | Amgevita | Celltrion Healthcare |
| Description | Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes. | A group of TNF inhibitor monoclonal antibody biosimilars recently approved in Singapore. These are indicated for managing conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. | Yuflyma is an adalimumab biosimilar, classified as a biologic Disease-Modifying Antirheumatic Drug (DMARD). It is used to treat immune-mediated inflammatory diseases by targeting and neutralizing TNF-alpha, helping to alleviate symptoms in conditions like psoriasis and arthritis. |
| Best for | International patients, Uveitis treatment, Hidradenitis suppurativa care and Ankylosing spondylitis patients | Rheumatoid arthritis patients, Crohn’s disease treatment, Psoriatic arthritis care and Ulcerative colitis management | Psoriatic arthritis, Inflammatory disease management and Biologic DMARD users |
| Action | |||
| Rating |
If you want the most balanced option to start with, I recommend:
"Amgevita (adalimumab) from Amgen Inc.."
I picked this because Amgevita provides a globally recognized biosimilar alternative for adalimumab therapy, backed by regulatory approvals in multiple major international markets.